Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions
Angela Hoye, MB, ChB*,
Kengo Tanabe, MD*,
Pedro A. Lemos, MD*,
Jiro Aoki, MD*,
Francesco Saia, MD*,
Chourmouzios Arampatzis, MD*,
Muzaffer Degertekin, MD*,
Sjoerd H. Hofma, MD*,
Georgios Sianos, MD, PhD*,
Eugene McFadden, MB, ChB, FACC*,
Willem J. van der Giessen, MD, PhD*,
Pieter C. Smits, MD, PhD*,
Pim J. de Feyter, MD, PhD, FACC*,
Ron T. van Domburg, PhD* and
Patrick W. Serruys, MD, PhD, FACC*,*
* Department of Interventional Cardiology, Erasmus MC, Rotterdam, the Netherlands
View larger version (17K):
[in a new window]
|
Figure 1 Kaplan-Meier curves for survival-free of death, acute myocardial infarction, or target vessel revascularization.
|
|
View larger version (37K):
[in a new window]
|
Figure 2 The percentage binary restenosis rate (>50% diameter stenosis) and reocclusion rate of Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital registry (RESEARCH) compared with published data from the patients treated with stent implantation in the randomized trials Stenting in Chronic Coronary Occlusion (SICCO) (5), Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche (GISSOC) (6), Stents in Total Occlusion for Restenosis Prevention (STOP) (7), and the Total Occlusion Study of Canada (TOSCA) (8). DS = diameter stenosis. *p < 0.05 compared with the results of RESEARCH;  p < 0.01 compared with the results of RESEARCH.
|
|
|
